Levi & Korsinsky is investigating Oncolytics Biotech Inc. (“Oncolytics” or the “Company”) (NasdaqCM: ONCY) for possible violations of federal securities laws. The investigation stems from the Company’s positive statements regarding its clinical trial for cancer drug Reolysin.

Click here to learn more about the investigation: http://zlk.9nl.com/oncolytics-biotech-oncy/ or call: 877-363-5972. There is no cost or obligation to you.

On November 21, 2013 Oncolytics issued a press release touting the “positive top-line data” of its Reolysin trial. The Company’s original goal was to measure survival, however in its report the Company reported the results of only 88 of the 118 patients in the trial, claiming others had received drugs that might bias overall survival results. An article on thestreet.com published the same day alleges that the Company’s CEO, Brad Thompson, is “shading the truth” in this report, citing nine “red flags” that cast doubt on the efficacy of the drug and the validity of the positive statements made.

If you own Oncolytics stock and wish to obtain additional information about the investigation and your legal rights, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/oncolytics-biotech-oncy/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:Levi & Korsinsky, LLPJoseph Levi, Esq.Eduard Korsinsky, Esq.30 Broad Street - 24th FloorNew York, NY 10004Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (866) 367-6510 www.zlk.com

Copyright Business Wire 2010